Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark.
Circ Cardiovasc Interv. 2009 Oct;2(5):392-400. doi: 10.1161/CIRCINTERVENTIONS.108.845636. Epub 2009 Aug 18.
We sought to describe the long-term prognosis after routine primary percutaneous coronary intervention (pPCI) in a contemporary consecutive population of patients with presumed ST-segment elevation myocardial infarction, compare it with similar results from the landmark DANAMI-2 trial, and to identify a possible impact of time of presentation and referral pattern.
Long-term prognosis in 1019 presumed ST-segment elevation myocardial infarction patients, treated according to modern routine pPCI during the year 2004, was analyzed and compared with similar data from the DANAMI-2 trial. Furthermore, we analyzed the impact of patient presentation to the angioplasty center during "off hours" (4 pm to 8 am plus weekends and holidays) and the impact of being referred from noninvasive hospitals. At 3 years, 20.4% in the routinely treated population versus 19.6% in the DANAMI-2 trial reached the combined end point of death, reinfarction, or stroke (P=0.68), whereas the all-cause mortality was 13.0% and 13.7%, respectively (P=0.65). Patients admitted during off hours had the same risk of reaching the combined end point of death, reinfarction, or stroke compared with patients admitted during office hours (hazards ratio, 1.04; 95% CI, 0.8 to 1.5; P=0.81). Door-to-balloon times of less than 90 minutes were achieved in 60% among patients admitted directly to an invasive center but only in 40% among transferred patients (P<0.001). Despite this difference, no difference in unadjusted or adjusted long-term prognosis was found between the 2 groups.
This study shows that ST-segment elevation myocardial infarction patients treated with contemporary routine pPCI achieve a similar long-term prognosis as patients in the landmark randomized pPCI trial (DANAMI-2). Furthermore, the long-term prognosis was the same regardless of whether the pPCI was performed during off hours or office hours. Thus, pPCI including transportation of patients from noninvasive centers can be applied successfully in a real-life population.
我们旨在描述在当代连续人群中接受常规经皮冠状动脉介入治疗(pPCI)的疑似 ST 段抬高型心肌梗死患者的长期预后,并将其与里程碑式 DANAMI-2 试验的类似结果进行比较,并确定可能存在的就诊时间和转诊模式的影响。
2004 年,1019 例疑似 ST 段抬高型心肌梗死患者按照现代常规 pPCI 进行治疗,对其长期预后进行分析,并与 DANAMI-2 试验的类似数据进行比较。此外,我们分析了在“非工作时间”(下午 4 点至早上 8 点,周末和节假日除外)和从非侵入性医院转诊时,患者就诊到介入中心的影响。3 年后,常规治疗人群中有 20.4%达到死亡、再梗死或卒中的联合终点,而 DANAMI-2 试验中有 19.6%(P=0.68),全因死亡率分别为 13.0%和 13.7%(P=0.65)。与在工作时间就诊的患者相比,在非工作时间就诊的患者达到死亡、再梗死或卒中联合终点的风险相同(风险比,1.04;95%CI,0.8 至 1.5;P=0.81)。直接进入介入中心的患者中,有 60%的患者门球时间小于 90 分钟,而转入患者中只有 40%(P<0.001)。尽管存在这种差异,但两组之间未发现调整后或未调整的长期预后存在差异。
这项研究表明,接受当代常规 pPCI 治疗的 ST 段抬高型心肌梗死患者的长期预后与里程碑式随机 pPCI 试验(DANAMI-2)中的患者相似。此外,无论 pPCI 是否在非工作时间或工作时间进行,其长期预后均相同。因此,包括将患者从非侵入性中心转运在内的 pPCI 可以在真实人群中成功应用。